Fungisome

The drug Fungisome, indicated for treatment of systemic mycosis and kala azar, is a liposomal formulation of Amphotericin B with strategically controlled and target release of the active ingredient. Fungisome is cheaper and more effective than its counterparts.

Amphotericin B has long been the drug of choice for life-threatening fungal infections, of the kind found in immuno-compromised patients, diabetics, AIDS victims and Cancer and organ transplant patients. However, its ability to kill disease is often offset by its severe side effects. By the time the drug has entered the body, traveled the bloodstream and reached the site of infection, toxic effects like fever and chills, kidney damage and severe breathing difficulty manifest. It has even been called 'Amphoter-rible' for this propensity to cause havoc in the patient's body.

In order to surmount this difficulty and make sure the drug did more good than harm, it was found that wrapping the drug's molecules into microscopic fat globules and then introducing them into the bloodstream did a much more efficient job.

Fungisome is a strategically designed targeted drug. It contains sterol as liposome constituent, necessary to prevent interaction with human cells and to raise specificity to target fungal cells, thus making it the safest formulation as proven by international experience of more than a decade.